Oriola
  • Sustainability
  • People and career
  • Newsroom
  • Contact Us
  • Log in to Digital Services

  • About us
  • Distribution services

    Specialist in pharmaceutical and health product distribution and logistics

    We manage a high-quality, GDP-compliant efficient supply chain for safe and reliable deliveries of pharmaceuticals and health and wellbeing products in the Nordics. Our specialised distribution services include quality control, warehousing and logistics, including modern cold chain technology and vaccine distribution expertise.

    • Distribution services
    • Pharmaceutical companies
      • Pharmaceutical companies
      • Vaccine distribution
      • Reporting and analytics
      • Warehousing and distribution
      • Advisory
    • Pharmacies
      • Pharmacies
      • Distribution
      • Dose dispensing
      • Research pharmacy network
      • Special licensed medicines
    • Veterinarians
      • Veterinarians
      • Special licensed medicines
      • Distribution
  • Wholesale services

    Nordic wholesale expertise for effortless growth

    We connect health and wellbeing suppliers and resellers through reliable, sustainable wholesale services. With deep Nordic market knowledge and a broad, high-quality product range, we help suppliers grow their reach and support resellers with reliable access, local expertise, and streamlined operations.

    • Wholesale services
    • Health and wellbeing products
    • Become a supplier
  • Advisory services

    Advisory Services  - precision with purpose

    We help pharmaceutical companies succeed with tailored services across the entire product lifecycle – from market entry and regulatory compliance to commercial strategy and market insights. Our advisory services combine deep knowledge of Nordic healthcare systems and regulatory requirements with a focus on operational efficiency and customer value. 

    • Advisory services
    • Clinical trial services
    • Market access and tenders
    • Market entry and commercial services
    • Market intelligence
    • Medical and regulatory affairs
    • Medical information and safety
    • Medical translations
    • Research services
    • Interim solutions
  • Investors

    Investor Relations – Financial Reports & News for Oriola

    Oriola has long experience and a strong position in the Finnish and Swedish pharmaceutical markets.

    • Investors
    • Oriola as an investment
      • Oriola as an investment
      • Strategy and targets
      • Business
      • Operating environment
      • Sustainable investment
      • Acquisitions and divestments
      • Analysts
    • Shares
      • Shares
      • Share price trend tool
      • Total return calculator
      • Dividend
      • Share capital and shares
      • Combination of share classes
    • Shareholders
      • Shareholders
      • Major shareholders
      • Flagging notifications
    • Reports and presentations
      • Reports and presentations
      • Annual Report
    • Financial information
      • Financial information
      • Key figures
      • Reporting segments
      • Long-term targets
      • Outlook
      • Near-term risks and uncertainty factors
      • Accounting principles
    • Corporate Governance
      • Corporate Governance
      • Shareholder meetings
        • Shareholder meetings
        • AGM 2025
        • AGM 2024
        • AGM 2023
        • AGM 2022
        • AGM 2021
        • AGM 2020
        • AGM 2019
        • AGM 2018
        • AGM 2017
        • AGM 2016
        • AGM 2015
        • AGM 2014
        • AGM 2013
        • AGM 2012
      • Shareholders’ Nomination Board
      • The Board of Directors
      • CEO and management
      • Remuneration
      • External Audit
      • Internal control
      • Risks
      • Insider register
      • Articles of Association
      • Shareholders' agreements
      • Disclosure Policy
    • Investor calendar
    • Investor relations
      • Investor relations
      • Subscribe to releases
    • Suomi
To Newsroom
  • Frontpage
  • Newsroom

Oriola’s Privacy notice has been updated

4.6.2018

At Oriola, the preparations for the EU General Data Protection Regulation (GDPR) started in the beginning of 2017. According to Oriola’s Legal Councel Petter Sandström, external professionals as well as all business areas at Oriola Sweden and Finland were engaged in the extensive project, and the project was successfully completed by May 25, 2018. 

More news

23.10.2025 | News

AI-powered data analysis in Medical Information – Breakfast event at Oriola Stockholm

Oriola warmly invites you to a complimentary breakfast event at our Stockholm office, where we’ll explore how artificial intelligence is transforming Medical Information services.

16.10.2025 | News

Invasive pneumococcal disease in Finland: New research reveals significant health and economic burden

A recent nationwide study, conducted by Oriola and published in Vaccine, highlights the substantial health and economic impact of invasive pneumococcal disease (IPD) among adults in Finland.

28.09.2025 | News

Decentralised elements in clinical trials - New service

Decentralised elements, such as home-visits, have been discussed and tested in small-scale projects. It is time for us as an industry to turn thoughts into actions. At Oriola, we intend to create a mobile study site that travels closer to patients' homes.

Oriola

Contact us

Follow us

  • Linkedin
Log in to digital services
About us
Investors
Sustainability
Career
Newsroom

Oiva reports
Privacy policy
Copyright (C) 2006-2025